Vale Jenny Kelsall

Vale Jenny Kelsall

Hepatitis NSW pays great respect to and mourns the sad passing of Jenny Kelsall, tireless advocate and leader in Australia’s harm reduction and viral hepatitis movement.

“We are greatly saddened by the loss, from hepatitis C related liver cancer, of our longstanding friend and colleague Jenny,” said Hepatitis NSW CEO Stuart Loveday.

“We shall miss Jenny’s wisdom, calm passion, understated humour and the great respect she had and showed for all people.

“As CEO of Harm Reduction Victoria, Jenny had a wonderful partnership-oriented approach to leadership in the viral hepatitis sector. Jenny will be sorely missed,” said Stuart.

Hepatitis NSW’s thoughts are with her family, friends and colleagues, at this very sad time.

Please follow this link to the Burnet Institute’s tribute to Jenny Kelsall…   https://www.burnet.edu.au/news/918_vale_jenny_kelsall

Read more

Associate Professor Alice Lee wins Cheryl Burman Award 2017

Via Hepatitis NSW, 24 Nov 2017.

Alice Lee is a gastroenterologist and hepatologist, clinical associate professor at Macquarie University and currently leads the liver services at Concord and Canterbury Hospitals.

Alice is also a founder of the Hepatitis B Free charity which was founded in 2013. Hepatitis B Free initially worked in remote Papua New Guinea, where volunteer health workers traveled on foot to vaccinate and provide basic health clinics for tribal villages. They decided to continue taking action towards addressing the huge unaddressed need of hepatitis B in other resource-poor areas, including North Korea. Alice has been instrumental in bringing hepatitis B awareness in the Asia Pacific region into the light.

Alice initiated a HBV screening program in NSW in 2014 using the Standard Diagnostics point of care rapid finger prick test, working with the Korean, Burmese, Chinese, Assyrian, Lebanese and Aboriginal communities in NSW.

Hepatitis NSW congratulates Associate Professor Alice Lee.

The Cheryl Burman Award is presented annually to an individual or team operating in NSW in recognition of their outstanding commitment to the advancement of treatment, support, information provision, management for people living with viral hepatitis.

Cheryl Burman, former Board member and President of the Hepatitis C Council of NSW – now Hepatitis NSW – died in 2011 after a long and arduous struggle with hepatitis C related liver disease.

Read more

A note of caution in hep C treatment ‘revolution’

Via Centre for Social Research in Health, UNSW, 10 Aug 2017

Tens of thousands of Australians have been cured of hepatitis C since new treatments were made universally available last year, and a report released last month said Australia is on track to eliminate hepatitis C by 2026. But while new treatments continue to dramatically reshape the landscape, data from the Centre for Social Research in Health’s (CSRH) Annual Report of Trends in Behaviour 2017: Viral Hepatitis in Australia underscores the need for caution.

Addressing stigma in healthcare settings, engaging marginalised communities in prevention, and continuing to trial innovative models of care will all be imperative if the ‘new era’ of treatment is to fulfil its promise, the report says.The report was presented on 10 August 2017 at the Australasian Viral Hepatitis Elimination Conference in Cairns.


Read more

$9million for research on hep C and drug dependency


Read more

Action required on falling treatment rates

Australia will not achieve the goal of eradicating hepatitis C without further action to ensure patients are identified and treated.

Speaking with PharmaDispatch following her appointment as president of Hepatitis Australia, Felicity McNeill PSM, said so much positive work has been done, with thousands of people cured, but all stakeholders must come together to address the fact treatment rates are in decline.


Read more

Investment in hep C treatment programs needed

Via Hepatitis Australia, 19 Dec 2017

Investment in hep C treatment programs needed to support Australia’s elimination goal.

Hepatitis Australia is urging government to invest in programs designed to increase the uptake of PBS-listed direct acting antivirals that cure hepatitis C.


Read more